What You Should Know:
– Proscia, a leader in artificial intelligence (AI)-powered pathology solutions, and Nucleai, a leading spatial AI biomarker company, announced a strategic partnership today. This collaboration aims to revolutionize precision medicine by integrating Nucleai’s advanced biomarker technology with Proscia’s Concentriq® software platform.
– By harnessing the power of AI and digital pathology, this partnership offers the potential to fundamentally improve the efficiency and effectiveness of developing new treatments and delivering exceptional patient care.
Precision Medicine Demands: New Role for Pathology Labs
The rise of precision medicine hinges on unlocking the power of data within pathology labs. Whole slide images, digital representations of tissue samples, offer a wealth of information crucial for tailoring treatments to individual patients. Nucleai’s AI technology analyzes these images, generating spatial maps that predict therapeutic outcomes.
Benefits for Patients, Labs, and Drug Developers
These AI-powered maps serve several purposes. For clinical trials, they can guide patient recruitment, ensuring participants are a good fit for the specific therapy being tested. Additionally, they can act as companion diagnostics, matching patients to the most effective treatments available.
Nucleai’s solutions boast a high adoption rate, with over 60% of the top 20 biopharmaceutical companies already utilizing their technology.
Proscia Concentriq: A Unified Platform for AI-powered Pathology
Proscia’s Concentriq platform serves as a central hub for all digital pathology data and AI-enabled workflows across the entire diagnostic process, from discovery to diagnosis. It boasts a growing library of AI applications from various sources, including Proscia itself, its customers, and leading third-party developers. This comprehensive platform addresses a diverse range of needs within the field of pathology. Concentriq is a trusted platform used by 14 of the top 20 pharmaceutical companies and major diagnostic labs worldwide.
Proscia Ready Partner Alliance Welcomes Nucleai
Nucleai also joins the Proscia Ready partner alliance today. This alliance unites solution providers dedicated to accelerating the widespread adoption of digital pathology within diagnostic laboratories and life science organizations.
